Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.16314 http://scihub22266oqcxt.onion/10.1111/ajt.16314 32946668!7537322!32946668     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2020 ; 20 (11): 3198-3205 Nephropedia Template TP {{tp|p=32946668|t=2020. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study |pdf=|usr=}}{{32946668}} gab.com Text Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32946668 #FOAvip The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID-19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID-19, 29 (24.8%) received tocilizumab. The 90-day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, P = .03). When compared to control patients matched by age, hypertension, chronic kidney disease, and administration of high dose corticosteroids, there was no significant difference in mortality (41% vs 28%, P = .27), hospital discharge (52% vs 72%, P = .26), or secondary infections (34% vs 24%, P = .55). Among patients who received tocilizumab, there was also no difference in mortality based on the level of oxygen support (intubated vs not intubated) at the time of tocilizumab initiation. In this matched cohort study, tocilizumab appeared to be safe but was not associated with decreased 90-day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID-19. Twit Text FOAVip Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32946668 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32946668 #FOAvip English Wikipedia <ref>{{Cite pmid|32946668}}</ref> Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study #MMPMID32946668 Pereira MR; Aversa MM; Farr MA; Miko BA; Aaron JG; Mohan S; Cohen DJ; Husain SA; Ratner LE; Arcasoy S; Uriel N; Zheng EX; Fox AN; Tsapepas DS; Emond JC; Verna EC Am J Transplant 2020[Nov]; 20 (11): 3198-3205 PMID32946668show ga The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID-19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID-19, 29 (24.8%) received tocilizumab. The 90-day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, P = .03). When compared to control patients matched by age, hypertension, chronic kidney disease, and administration of high dose corticosteroids, there was no significant difference in mortality (41% vs 28%, P = .27), hospital discharge (52% vs 72%, P = .26), or secondary infections (34% vs 24%, P = .55). Among patients who received tocilizumab, there was also no difference in mortality based on the level of oxygen support (intubated vs not intubated) at the time of tocilizumab initiation. In this matched cohort study, tocilizumab appeared to be safe but was not associated with decreased 90-day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID-19. |*Organ Transplantation[MESH] |*SARS-CoV-2[MESH] |*Transplant Recipients[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |COVID-19/*epidemiology[MESH] |Comorbidity[MESH] |Female[MESH] |Graft Rejection/epidemiology/*prevention & control[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH]Tocilizumab for severe COVID-19 in solid organ transplant recipients: (epmc).pdf DeepDyve Pubget Overpricing